about
Structure of the bacterial type II NADH dehydrogenase: a monotopic membrane protein with an essential role in energy generationIon Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosisPharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment durationCharacterization of the type 2 NADH:menaquinone oxidoreductases from Staphylococcus aureus and the bactericidal action of phenothiazinesEnergetics of Respiration and Oxidative Phosphorylation in Mycobacteria.Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1The tuberculosis drug discovery and development pipeline and emerging drug targets.The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress.Tuberculosis drug discovery and emerging targets.Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions.The mechanism of catalysis by type-II NADH:quinone oxidoreductases.Thioridazine inhibits gene expression control of the cell wall signaling pathway (CWI) in the human pathogenic fungus Paracoccidioides brasiliensis.The ATP synthase inhibitor bedaquiline interferes with small-molecule efflux in Mycobacterium smegmatis.Novel non-neuroleptic phenothiazines inhibit Mycobacterium tuberculosis replication.Challenging the Drug-Likeness Dogma for New Drug Discovery in TuberculosisEfflux Pumps in Mycobacteria: Antimicrobial Resistance, Physiological Functions, and Role in Pathogenicity
P2860
Q27688947-FDD799E0-612F-49CA-8642-885949936C06Q28550401-EE357ED5-60BD-4DA2-B028-1F44275C6C18Q30377051-E3C0B942-FB9D-498E-9785-6B3380E2BA11Q33717526-70CA8C91-BBAD-4DF0-87A7-555AEE817848Q34383371-A84F2CAE-DDC4-4399-BE35-59F87C667EAEQ35031417-A8033A27-38B8-46DE-8D9C-0B9BCF56EF47Q35664209-79523EDD-0893-4797-96AD-C4517B4B232DQ35670401-1BE12DDA-3690-466D-8C7C-197C1790CB7DQ38219605-A5B588A4-B64B-4045-BA69-25A2BDA21E3BQ38672958-A3ADF4BE-B6F9-42AC-BB6B-F947B1B28E02Q39032314-B149427C-233F-40D1-A00D-03657C23130AQ40763094-BA3C6D5E-03DA-4709-9CEB-AC9EDB457BC4Q42211078-8A035FE4-CCC1-4447-9026-A8EA1DD8F410Q42227061-963903F7-30B8-4DE1-96BB-BC3F7EB670F9Q57656314-54BF74E2-8D01-4E13-A9F4-595DBF470D3AQ57656351-173B6EA0-6130-45B4-9477-2D9E9E2ADCA9
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Antitubercular pharmacodynamics of phenothiazines
@ast
Antitubercular pharmacodynamics of phenothiazines
@en
type
label
Antitubercular pharmacodynamics of phenothiazines
@ast
Antitubercular pharmacodynamics of phenothiazines
@en
prefLabel
Antitubercular pharmacodynamics of phenothiazines
@ast
Antitubercular pharmacodynamics of phenothiazines
@en
P2093
P2860
P50
P356
P1476
Antitubercular pharmacodynamics of phenothiazines
@en
P2093
Ashley J Warman
Nicholas E Fisher
Paul M O'Neill
P2860
P304
P356
10.1093/JAC/DKS483
P407
P577
2012-12-09T00:00:00Z